-
10:39:35 PM

BMY Stock News

11/02/22 6:59 AM
NYSE : BMY
Data Reinforcing Impact of Bristol Myers Squibb Cardiovascular Portfolio to be Presented at American Heart Association Scientific Sessions 2022
Bristol Myers Squibb today announced the presentation of research demonstrating the strength of the company’ s cardiovascular franchise at the American Heart Association’ s annual Scientific Sessions, taking place in-person and virtually November 5-7, 2022. “The AHA annual Scientific Sessions is an important congress for us to share new data that is...
RHEA-AI
neutral
10/26/22 2:00 AM
NYSE : BMY
covid-19
New Zeposia (ozanimod) Data Highlight COVID-19 Outcomes and Preservation of Long-Term Cognitive Function from Separate Analyses in Patients with Relapsing Forms of Multiple Sclerosis
Bristol Myers Squibb today announced new retrospective analyses on serologic responses and clinical outcomes with COVID-19 vaccination in participants treated with Zeposia from the ongoing Phase 3 DAYBREAK open-label extension study in relapsing multiple sclerosis. “These data are of clinical importance for physicians treating multiple sclerosis,...
RHEA-AI
neutral
10/25/22 7:31 PM
NYSE, Nasdaq : BMY, TSVT
earnings
Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
Bristol Myers Squibb today reports results for the third quarter of 2022, which reflect strong in-line and new product portfolio growth. “Our strong results reflect growth of our in-line and new product portfolios,” said Giovanni Caforio, M.D., board chair and chief executive officer, Bristol Myers Squibb.“ Our teams continue to progress our pipeline and achieve...
RHEA-AI
neutral
10/25/22 1:04 PM
NYSE : BMY
clinical trial
The Robert A. Winn Diversity in Clinical Trials Award Program Announces the Second Group of Physicians to be Trained in the $114 Million Program
The Bristol Myers Squibb Foundation, together with Virginia Commonwealth University, the American Association for Cancer Research and Gilead Sciences, Inc., today announced that an additional 64 physicians have been selected to receive the Robert A. Winn Diversity in Clinical Trials Career Development Award. "Clinical trials are at the heart of all medical...
RHEA-AI
very positive
10/24/22 6:59 AM
NYSE : BMY
New Data Presented at the American College of Gastroenterology Annual Scientific Meeting Demonstrate Continuous Zeposia (ozanimod) Treatment Prevents Disease Relapse Over One Year in 86.1% of Patients Who Respond at the End of the Induction Period
Bristol Myers Squibb today announced new post hoc analyses from the Phase 3 True North study evaluating the duration of response following continuous Zeposia treatment for up to one year and following treatment interruption in patients with moderately to severely active ulcerative colitis. "Understanding the duration of response after continuous...
RHEA-AI
negative
10/21/22 6:59 AM
NYSE : BMY
U.S. Food and Drug Administration (FDA) Accepts Supplemental New Drug Application for CAMZYOS® (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy to Reduce the Need for Septal Reduction Therapy
Bristol Myers Squibb today announced that the U.S. Food and Drug Administration has accepted its supplemental new drug application for CAMZYOS ® for an expanded indication to reduce the need for septal reduction therapy. CAMYZOS is currently FDA approved for the treatment of adults with symptomatic New York Heart Association class II-III obstructive...
RHEA-AI
neutral